Reduced Expression of the Putative Tumour Suppressor Spinophilin Is an Adverse Prognostic Factor in Squamous Cell Carcinoma of the Head and Neck
Alena M Aigelsreiter, Ariane Aigelsreiter, Martin Wehrschuetz, Anna Ress, Karin Koller, Thomas Kiesslich, Silvia Schauer, Thomas Bauernhofer, Martin Pichler. Medical University of Graz, Graz, Styria, Austria; Paracelsus Medical University, Salzburg, Styria, Austria
Background: Spinophilin (SPN), a multifunctional intracellular scaffold protein, has been involved in carcinogenesis of lung and other types of cancer. To date, there exist no data about the role of SPN in squamous cell carcinoma of the head and neck (SCCHNs).
Design: In the present study, we evaluated SPN expression in SCCHN tumor tissue by immunohistochemistry in 85 patients who underwent a curative tumor resection. The SPN expression was correlated with clinico-pathological characteristics and multivariate Cox proportional models were used to define its prognostic relevance.
Results: Immunoreactivity for SPN was reduced in 40 (47%) tumors and 9 (10.5%) cases showed complete loss of SPN. Kaplan Meier curve analysis demonstrated that reduced SPN expression is associated with poor survival (p=0.022, log-rank test). Multivariate COX regression analysis confirmed clinico-pathological parameters as independent prognostic factors of survival.
Conclusions: A reduced expression of SPN is frequently found in SCCHNs, which indicate an important role of SPN in the pathogenesis of SCCHNs. Based on our results SPN may represent a novel prognostic factor for predicting patient's outcome in SCCHNs.
Category: Head & Neck
Wednesday, March 6, 2013 9:30 AM
Poster Session V # 205, Wednesday Morning